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Summary 
T cell stimulation by the human immunodeficiency virus 1 gpl60-derived peptide pl8 presented 
by H-2D a class I major histocompatibility complex molecules in a cell-free system was found 
to require proteolytic cleavage. This extracdlular processing was mediated by peptidases present 
in fetal calf serum. In vitro processing of p18 resulted in a distinct reverse phase high performance 
liquid chromatography profile, from which a biologically active product was isolated and sequenced. 
This peptide processing can be specifically blocked by the angiotensin-1 converting enzyme (ACE) 
inhibitor captopril,  and can occur by exposing p18  to purified ACE.  The ability of naturally 
occurring extracellular proteases to convert inactive peptides to T  cell antigens has important 
implications for understanding cytotoxic T lymphocyte responses in vivo, and for rational peptide 
vaccine design. 
T  lymphocytes that express CD4 accessory molecules gener- 
ally recognize an antigenic fragment of an exogenous 
protein bound  to  a  class  II MHC  molecule.  In contrast, 
CD8 + T cells generally recognize an antigenic fragment of 
an endogenous protein bound to a class I molecule (1, 2). 
Exceptions  to  this  model,  where exogenous proteins  are 
processed and presented on class I MHC molecules (3-5), 
may play a role in aberrant immune responses and may be 
useful for design of noninfectious CTIAnducing vaccines. 
Specific extracellular peptidases can favor generation or de- 
struction of optimally sized (6-10) class I-binding peptides 
from larger protein fragments. This processing can explain 
the efficacy of many peptides that exceed the optimal length 
in in vitro experiments, and is one possible mechanism by 
which exogenous proteins or peptides can sensitize ceUs to 
class I-restricted lysis. 
Materials and Methods 
Peptides andPeptide Sequencing.  The HIV gp160 envelope  glyco- 
protein-derived peptides, p18 (R.IQRGPGRAFVTIGK)  (11) and 
p18-I-10 (RGPGRAFVTI) (T. Takeshita, manuscript in prepara- 
tion),  were synthesized by t-BOC chemistry and purified by re- 
verse phase HPLC. Recovered HPLC fractions were sequenced by 
automated Edman degradation on a modal 470A sequenator and 
fractions were identified by amino acid analysis on a model 120A 
FFH analyzer  (both from Applied Biosystems,  In~, Foster  City, CA). 
Soluble H-2D ~ Class I  Protein.  Soluble H-2D  d protein  was 
af~nity purified from supernatants of L cells transfected with an 
H-2D  d genomic  construct  consisting  of DNA  encoding  the 
H-2D  d celc~zcx3  domains and the 27 COOH-terminal amino acid 
residues of the soluble Q10  b molecuh (12). 
Exopeptidases andlnhih'tors.  Carboxypeptidase N (EC 3.4.17.3) 
(Calbiochem Corp., La Jolla, CA), ACE  1 angiotensin-1 converting 
enzyme (EC 3.4.15.1), captopril (both from Sigma Chemical Co., 
St. Louis, MO), and potato carboxypeptidase  inhibitor (Calbiochem 
Corp.) were dissolved in PBS. Plummer's inhibitor was dissolved 
in acidified deionized water. E-64 (both from Calbiochem Corp.) 
was dissolved in  33%  DMSO  (final concentration  was always 
<1.7%). 
HPLC Fractionation of p18.  40 #1 of 2.5 mM p18 was added 
to 160/zl 1% OVA or 1% BSA for 15 h at 37~  100/~1 of each 
sample was spun through a Centricon 3 falter (Amicon, Beverly, 
MA) into 100 ~1 of 1% BSA. The samples were injected into a 
4.6 mm x  250 mm C18 reverse phase column (Vydac, Hesperia, 
t Abbreviations used in this paper: ACE, angiotensin-1  converting  enzyme; 
B2-m, Bz-microglobulin. 
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rain. The flow rate was I ml/min and the absorbance was moni- 
tored at 220 nm. Forty 1-ml fractions were collected, dried down 
in a Spin-Vac, and resuspended  in 200/zl ddonized water. The pooled 
and unpooled fractions  were diluted 1:8 in 0.1% BSA in PBS, filter- 
sterilized and evaluated for functional activity. 
Stimulation of the T Cell Hybridoma with Purified Class I.  Soluble 
H-2D  d protein  was coated onto Immulon 4 plates (Dynatech 
Labs., Inc., Chantilly, VA) at 0.1-0.25/.tg/well  in 50-p.1 PBS for 
2-2.5 h at 37~  The plates were washed twice with 200-/~1 PBS 
and blocked  for 30-60 rain with the incubation medium to be added 
during the peptide pulsing period. 
Peptide and human ~z-microglobulin  (~rm) (Calbiochem  Corp.) 
(0.2/zg/well) were added  to the incubation  media,  0.5% BSA (Sigma 
Chemical Co. fraction V), OVA (Sigma Chemical Co. grade V), 
or FCS (Hyclone Laboratories Inc., Logan, UT), to give a final 
volume of 200 tzl/well, and the plates were incubated at 37~  and 
7.5% CO2 for 22-26 h. The plates were then washed twice with 
PBS and 2 x  104 B4.2.3 T-hybridoma cells (anti-p18 plus H-2D a) 
(12) were added per well in DMEM supplemented with 10% FCS, 
2-mM glutamine, nonessential amino acids, 50/~g/ml gentamicin, 
and 5  x  10 -s M 2-ME (complete medium). The plates were in- 
cubated from 16-20 h at 37~  and 7.5% CO2. The cells were 
then pulsed with 1-/~Ci [3H]thymidine (ICN Biomedicals, Inc., 
Costa Mesa, CA), and collected  4-8 h later for counting the amount 
of incorporated label to evaluate growth inhibition (13). 
Response of T  Cell Hybridoma  to Cell-surface Class I.  H-2D d 
positive L cells (2  x  104/well) with peptide, 3T3 neomycin resis- 
tance gene transfectant calls, or 3T3 gp160 gene transfectant calls 
were added to each well with 104 B4.2.3 T-hybridoma  cells. After 
an overnight incubation, 50/zl/well of supernatant was harvested 
and freeze-thawed. These supernatants were added to 4  x  103 
CTLL-2 cells in ILPMI complete medium to give a final volume 
of 200 ~tl/well. After an 18-h incubation, 1-~Ci [3H]thymidine 
was added to each well. 4 h later, the CTLb2 cells were collected 
and counted for incorporated thymidine. 
Results  and  Discussion 
The HIV-1 (IIIB) gp160 envelope glycoprotein-derived pep- 
tide, p18, is 15 amino acids in length (residues 315-329).  It 
is  the  immunodominant CTL  determinant  of gp160  in 
H-2D  d mice (11, 14), and is also able to sensitize  syngeneic 
cells for lysis by CTL from HIV-l-infected humans (15). 
Previous studies of  the ability of this peptide to form a stimula- 
tory complex with  soluble purified H-2D  a molecules in 
vitro, indicated that two activities of FCS were required for 
recognition of p18 by a specific T  cell hybridoma. One ac- 
tivity was that of/32-m (12, 16-19),  and the other activity 
could be provided by OVA. Most batches of BSA were un- 
able to replace this ~2-m-independent effect of FCS. The re- 
cent evidence concerning the importance of length in the ac- 
tivity of peptides presented by MHC class I molecules, and 
the identification of a truncation of p18, p18-I-10 (residues 
318-327),  with 101-102-fold greater potency of T cell stim- 
ulation (T. Takeshita,  manuscript in preparation) prompted 
us to consider the possibility that OVA and FCS were pro- 
cessing p18 to an active,  shorter peptide. 
Thus, we compared the two peptides of different lengths 
in our ceU-free system for their functional binding to class 
I MHC molecules in the presence of  BSA, OVA, or FCS (Fig. 
1). This binding was evaluated through activation of the B4.2.3 
pl8-specific T  cell hybridoma, measured by growth inhibi- 
tion (13). With p18, FCS or OVA was required for significant 
activation of B4.2.3. In contrast, this activation was decreased 
by FCS or OVA when p18-I-10 was used. The concentration 
of p18-I-10 which gave half-maximal stimulation was 10-11 M 
when added in BSA.  This concentration was  101-102-fold 
less than the half-maximal concentration of p18-I-10 used in 
FCS,  and 103-fold lower than the half-maximal concentra- 
tion of p18-I-10 when used in OVA. 
One possible  explanation of these results is that proteo- 
lytic enzymes in OVA and FCS degrade the p18  15mer  to 
a smaller active form, and also reduce the active 18-I-10 10mer 
to an inactive form. To evaluate this hypothesis, we incubated 
p18 with either OVA or BSA overnight, size-fractionated  the 
small MW peptides away from the OVA or BSA, and ana- 
lyzed them by reverse-phase HPLC (Fig.  2).  A decrease in 
the amount, and a slight increase of the retention time of 
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Figure 1.  (a) B4.2.3 response to p18 is dependent on OVA or FCS. The functional  response assayed  by growth inhibition  was measured as described 
in Materials  and Methods. (--O--) p18 in 0.5% BSA; (-I--) p18 in 0.5% OVA; (~)  p18 in 0.5% FCS. (b) B4.2.3 growth inhibition  response to 
p18-I-10 is decreased  by OVA or FCS. (--O--) 18-I-10 in 0.5% BSA; (-l-) 18-1-10 in 0.5% OVA; (--Jr-) 18-I-10 in 0.5% FCS. No peptide in BSA, 
475,500 cpm _+ 5710 sem. No peptide in OVA, 512,800 cpm _+ 34,400 sem. No peptide in FCS, 509,900 cpm _+ 3,530 sem. Results  are expressed 
as cpm -+  sem. This experiment was done in duplicate, and similar results were obtained in three experiments. 
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Figure 2.  HPLC fractions of treated  p18 were collected and evaluated 
for growth inhibition of B4.2.3  as described in Materials and Methods. 
(a) Reverse phase HPLC fractions  of OVA-treated p18 and  their ability 
to functionally  bind H-2D  d.  (~)  220-rim  absorbance;  (--O--) re- 
sponse of B4.2.3 to 1:5 dilution of fractions in 0.5% BSA added to H-2D  d 
coated plates;  (-0-)  1:25 dilution of fractions  in 0.5%  BSA added  to 
H-2D  d coated plates. B4.2.3  incorporated  345,000 cpm with H-2D  a in- 
cubated  with 0.5% BSA. B4.2.3  incorporated  11,900 cpm with H-2D  a 
incubated  with 0.05/zM 18-I-10 in 0.5% BSA. (b) Reverse phase HPLC 
fractions of BSA-treated p18 and their ability to functionally bind H-2D  d. 
(----'--) 220-nm absorbance;  (-A-) response of B4.2.3  to 1:5 dilution 
of fractions in 0.5% BSA added to H-2D  d coated plates; (--&-) 1:25 di- 
lution of fractions  in 0.5% BSA added  to H-2D  a coated plates. B4.2.3 
incorporated 384,000 cpm with }-I-2D  d incubated with 0.5% BSA. 84.2.3 
incorporated  9,649 cpm with H-2D  d incubated with 0.05/~M 18-1-10 in 
0.5%  BSA. Similar  results were obtained  in two experiments. 
the major peak of p18 in PBS (data not shown) was seen in 
the OVA-treated peptide, but not in the BSA-treated peptide. 
The HPLC profile of the OVA-treated p18 also differed from 
the BSA-treated p18 in amount and retention time of several 
minor peaks. To determine in which fractions of the OVA- 
treated p18 the T cell-stimulatory activity eluted, the frac- 
tions were assayed for presentation by plate-bound H-2D d. 
The active growth-inhibiting material was in fractions 26 and 
27, eluting later than the p18 major peak. These fractions 
had very little 220-nm absorbance. The BSA-treated p18 frac- 
tions were unable to inhibit the growth of the T  cell hy- 
bridoma. This observation suggested that a very small frac- 
tion of the processed p18 was a highly active peptide, as has 
been noted for the SV12 peptide and its synthetic contaminants 
(8). However, in contrast to the latter case, this active pep- 
tide is not a contaminant of the original p18 preparation. 
The active fractions were pooled and the sequence of the pep- 
tide was determined to be XIQRGPGRAFVTI, which is 
identical to p18 lacking two COOH-terminal residues. A clear 
peptide sequence was difficult to obtain from the active frac- 
tion generated by FCS treatment of p18, probably because 
of a more complex proteolytic system  and contaminating 
serum peptides. The activity in the OVA appeared to be that 
of a carboxypeptidase, removing the two COOH-terminal 
residues  from p18. 
To identify the carboxypeptidase that processes p18 in FCS, 
we titrated four carboxypeptidase inhibitors into p18 FCS 
mixtures, adding them to plate-bound H-2D  d. The inhibi- 
tots used were potato carboxypeptidase inhibitor (20), which 
blocks tissue carboxypeptidases  A and B, Plummer's inhib- 
itor (21), which blocks carboxypeptidase N  (serum carbox- 
ypeptidase B), captopril (22), which blocks ACE or peptidyl 
dipeptidase A, and E-64 (23), which blocks cathepsin B (pep- 
tidyl dipeptidase B). In the presence of FCS, nanomolar con- 
centrations of captopril blocked p18-dependent stimulation 
of B4.2.3 (Fig. 3 a). The blocking of FCS processing of p18 
occurred at captopril concentrations 104-10S-fold lower than 
that of any of the other carboxypeptidase inhibitors. This 
result suggested ACE (24, 25), a key regulator of vasoactive 
peptides, as a major serum processor of p18. Thus, we at- 
tempted to process p18 in the absence of serum or OVA using 
rabbit lung ACE (Fig. 3 b). The purified ACE was able to 
process p18 without serum, whereas human carboxypepti- 
dase N  was unable to do so. ACE was not required for T 
cell hybridoma stimulation by p18-I-10, and had some in- 
hibitory effect at high concentrations using both p18 and 
p18-I-10. 
We then evaluated whether the role of ACE in processing 
p18 for presentation by purified class I molecules would also 
apply to cell-surface class I molecules. This experiment was 
done using H-2Dd-transfected L  cells as the antigen pre- 
senting cells. Peptides p18 and p18-I-10 were titrated in the 
presence of 10 -s M captopril or Plummer's inhibitor in the 
presence of medium containing FCS (Fig. 4 a). The p18 con- 
centration required for half-maximal lymphokine  production 
by the hybridoma was increased by 103-104-fold in the pres- 
ence of captopril. Captopril had no significant effect on p18- 
1-10, excluding a  direct  cellular  effect  of captopril,  and 
Plummer's inhibitor and E-64 (data not shown) had no effect 
on p18. In contrast, stimulation of the B4.2.3 hybridoma 
is not affected by captopril or Plummer's inhibitor when a 
transfectant cell (11) that expresses the gp160 envelope pro- 
tein and H-2D  a is used as the antigen source (Fig. 4 b). The 
data in Fig. 4 a suggest that the ACE extracellular processing 
demonstrated in the cell-free system is applicable to the cell- 
surface system. The data in Fig. 4 b suggest that the intracel- 
lular processing of the whole antigen is not dependent on 
an ACE-like activity, or occurs in a cellular compartment in- 
accessible to captopril. 
We have demonstrated that ACE activity is required for 
the processing of a long peptide (15 residues), and that serum 
can inactivate a short peptide (10 residues). ACE can remove 
COOH-terminal dipeptides from many substrates at varying 
rates. However, peptides with a penultimate proline are not 
cleaved (25). The serum processing of a peptide to the cor- 
rect COOH-terminus for MHC binding would depend on 
the accumulation of a particular kinetic intermediate in pro- 
teolysis. The observation that the active peptide produced 
by OVA's exopeptidases  is a 13mer with the same COOH 
terminus as the active synthetic peptide 18-1-10, suggests the 
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Figure 3.  Effect  of carboxypeptidase inhibitors and carboxypeptidase on p18 processing. (a) Effect of carboxypeptidase inhibitors on p18 functional 
binding to H-2Da in FCS. Growth inhibition in the presence of (-&-) potato carboxypeptidase inhibitor; (-0-) Plummer's inhibitor; (-A-) cap- 
topril; (--dr) E-64 was measured as described in Materials and Methods. B4.2.3 thymidine incorporation without inhibitors. No peptide in FCS 145,000 
cpm  +  11,200 sem; 1 ~M p18 in FCS 27,800 cpm  +  4,400 sem. No peptide in BSA 145,000 cpm  +_  7,000 sere; 1/~M p18 in BSA 146,000 cpm 
_+  1,600 sem. The carboxypeptidase inhibitors were titrated as shown in 1/zM p18 and 0.5% FCS. The experiment was done in triplicate and results 
are shown  :t:  sem. Similar results were obtained in three experiments.  (b) ACE processes p18 into an active form in BSA. Growth inhibition was 
assessed as above. (-O-) p18 plus ACE; (-0-) 18-I-10 plus ACE; (-&-) p18 plus carboxypeptidase N; (--dr) 18-1-10  plus carboxypeptidase N. B4.2.3 
thymidine incorporation without carboxypeptidases. No peptide in FCS 429,600 cpm _+ 21,000 sere. No peptide in BSA 411,800 cpm +  29,200 sem; 
1/~M p18 in FCS 112,600 +  13,200 sem; 1/~M p18 in BSA 449,600 cpm  _+  21,600 sem; 0.1 pM 18-I-10 in FCS 13,100 cpm  +_  1,000 sem; 0.1 
/~M 18-I-10 in BSA 5,500 cpm  +_  120 sem. Carboxypeptidase  N  and ACE were titrated in 0.5% BSA. The experiment  was done in triplicate and 
results are shown  +  sem. Similar results were obtained in two experiments. 
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Figure 4.  Effect  of captopril on p18 and gp160 processing and presenta- 
tion by cell-surface class I. (a) The B4.2.3 lymphokine response to p18 
and H-2D  d positive L cells in FCS is significantly decreased by captopril. 
(--O--) p18; (-'UP-) p18 plus captopril; (--~-) p18 plus Plummer's inhib- 
itor; (---e---) 18-I-10; (---g---) 18-I-10 plus captopril;  (---A--) 18-I-10 
plus Plummer's  inhibitor. CTLD2 thymidine  incorporation  in the absence 
of peptide was <600 cpm. Captopril, Plummer's inhibitor, or no carbox- 
key processing event contributed by OVA or FCS occurs at 
the COOH terminus. Other peptidases might be involved 
either before or after class I binding as suggested by Falk et 
al. (26). The ACE inhibitor captopril can increase or decrease 
the stimulation of a T cell hybridoma specific for a murine 
cytomegalovirus  (MCMV) pp89 peptide depending on the 
COOH-terminal sequence flanking the core peptide (data not 
shown). The role of ACE and exopeptidases in general needs 
to be evaluated with different peptide fragments of gp120, 
and other class I-restricted  antigens. 
There are a number of reports in the literature regarding 
exogenous antigens being recognized by class I-restricted T 
cells, either through extraceUular processing or specialized 
class I presenting cells (3, 5, 27, 28). ACE and other pepti- 
dases may trim fragments of soluble antigenic proteins in vivo. 
The availability of fragments of soluble antigenic proteins 
may depend on specialized cells that can release proteases or 
endocytose  whole  soluble  antigen  and  release fragments 
(29, 30). 
ypeptidase inhibitor was added to give a final concentration of 10-s M 
and peptide (p18 or 18-I-10) was titrated.  Results are shown as triplicates 
+ sere. Three experiments gave similar results. (b) The B4.2.3 lymphokine 
response to gp-160 transfeeted H-2D  a positive 3T3 cells is not decreased 
by captopril.  (-&-) gp160 transfectant; (-U]-) gp-160 transfectant plus 
captopril;  (-Z~) gp-160 transfectant plus Phmmer's inhibitor; (---0--) 
neo transfeetant. CTLb2 thymidine incorporation in the absence of tran- 
feeted L cells was <500 cpm. Captopril,  Plummer's inhibitor, or no car- 
boxypeptidase  inhibitor were  added  to  give  a  final  concentration of 
10-s M, and transfeetant 3T3 cells were titrated as shown.  Results are 
shown as triplicates  _+  sem. Three experiments gave similar results. 
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peptides may lead to generation of noninfected false targets 
competing for the CTL response against vitally infected cells. 
This processing may also amplify a CTL response beneficial 
to the host. Serum enzymes can also lead to degradation of 
class I antigenic peptides (31).  Pathogens could potentially 
follow different clinical courses based on their antigenic pro- 
tein's ability to be processed or degraded extracellularly.  PBLs 
from HIV-infected patients can recognize p18 presented by 
syngeneic cells (15). Since ACE inhibitors are currently being 
used for their hemodynamic benefits in the treatment of HIV 
cardiomyopathy (32),  it will be useful to evaluate patients 
for the possible immunologic effects of this class of drugs. 
A number of laboratories are investigating the use of syn- 
thetic peptides for immunization or other immunomodula- 
tory effects. Understanding the specificity of peptide processing 
in human plasma and other body fluids is of vital importance 
in the direct design of these synthetic peptides and the pos- 
sible use of peptidase inhibitors in conjunction with them. 
This understanding could lead to the development of highly 
effective vaccines. 
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